Daniel E. Furst
Impact in
- Pathology and Forensic Medicine top 0.01%
- Systemic Sclerosis and Related Diseases
- Rheumatology top 0.02%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Osteoarthritis Treatment and Mechanisms
Papers in
-
- Systemic Sclerosis and Related Diseases 226
- Rheumatology 125
- Rheumatoid Arthritis Research and Therapies 112
- Systemic Lupus Erythematosus Research 11
- Co-authors
- Dinesh Khanna (102 shared papers)Philip J. Clements (68 shared papers)Steven A. Fischkoff (3 shared papers)Elliot Chartash (3 shared papers)Michael H. Weisman (12 shared papers)Edward Clark Keystone (9 shared papers)Charles A. Birbara (3 shared papers)Donald P. Tashkin (33 shared papers)
- Journals
- Lara D. Veeken (42 papers)Annals of the Rheumatic Diseases (37 papers)Arthritis Care & Research (26 papers)Seminars in Arthritis and Rheumatism (20 papers)Arthritis & Rheumatology (18 papers)
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Daniel E. Furst
429 papers receiving 38.2k citations
Daniel E. Furst's Hit Papers
Peers
Comparison fields: 5 of 165
- Pathology and Forensic Medicine 15.4k
- Rheumatology 11.1k
- Nephrology 2.2k
- Pulmonary and Respiratory Medicine 3.7k
- Pharmacology 832
Countries citing papers authored by Daniel E. Furst
This map shows the geographic impact of Daniel E. Furst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Furst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Furst more than expected).
Fields of papers citing papers by Daniel E. Furst
This network shows the impact of papers produced by Daniel E. Furst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Furst. The network helps show where Daniel E. Furst may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel E. Furst, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 446 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative Hit paper breakdown → | 2013 | 2813 |
| 2 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Hit paper breakdown → | 2015 | 2374 |
| 3 | 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative Hit paper breakdown → | 2013 | 2284 |
| 4 | Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Hit paper breakdown → | 2003 | 1508 |
| 5 | Cyclophosphamide versus Placebo in Scleroderma Lung Disease Hit paper breakdown → | 2006 | 1329 |
| 6 | 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Hit paper breakdown → | 2012 | 1247 |
| 7 | American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis Hit paper breakdown → | 2008 | 1196 |
| 8 | Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis Hit paper breakdown → | 2006 | 996 |
| 9 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Hit paper breakdown → | 2015 | 962 |
| 10 | American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials Hit paper breakdown → | 2011 | 883 |
| 11 | Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial Hit paper breakdown → | 2016 | 828 |
| 12 | Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist Hit paper breakdown → | 2004 | 569 |
| 13 | 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis Hit paper breakdown → | 2012 | 563 |
| 14 | Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial Hit paper breakdown → | 2016 | 556 |
| 15 | Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2020 | 500 |
| 16 | Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma Hit paper breakdown → | 2018 | 439 |
| 17 | Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). | 2003 | 428 |
| 18 | 2010 | 405 | |
| 19 | 2006 | 399 | |
| 20 | Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis Hit paper breakdown → | 2017 | 397 |
About Daniel E. Furst
Daniel E. Furst is a scholar working on Pathology and Forensic Medicine, Rheumatology, Pharmacology, Statistics and Probability and Pharmacology, having authored 446 papers that have together received 40.2k indexed citations. Recurring topics across this work include Systemic Sclerosis and Related Diseases (226 papers), Rheumatoid Arthritis Research and Therapies (112 papers), Pharmacogenetics and Drug Metabolism (21 papers), Pulmonary Hypertension Research and Treatments (16 papers), Statistical Methods in Clinical Trials (15 papers), Inflammatory mediators and NSAID effects (15 papers), Systemic Lupus Erythematosus Research (11 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers). The work is most often cited by research in Pathology and Forensic Medicine (15.4k citations), Rheumatology (11.1k citations), Nephrology (2.2k citations), Pulmonary and Respiratory Medicine (3.7k citations) and Pharmacology (832 citations). Daniel E. Furst has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Dinesh Khanna, Philip J. Clements, Steven A. Fischkoff, Elliot Chartash, Michael H. Weisman, Edward Clark Keystone, Charles A. Birbara, Donald P. Tashkin, Michael E. Weinblatt and Larry W. Moreland. Their work appears in journals such as Lara D. Veeken, Annals of the Rheumatic Diseases, Arthritis Care & Research, Seminars in Arthritis and Rheumatism and Arthritis & Rheumatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.